Genzyme has announced new magnetic resonance imaging (MRI) data from the Lemtrada clinical development program.
In relapsing remitting multiple sclerosis (RRMS) patients treated with Lemtrada in the Phase III pivotal studies, MRI effects observed in the two-year trials were maintained through two additional years in the extension study (years three and four). After the initial two courses of treatment in the pivotal studies, which were given at month zero and at month 12, approximately 70 percent of Lemtrada patients did not receive additional Lemtrada treatment during the following three years, through month 48............. Read More - http://www.ms-uk.org/lemtrada
Study finds brain atrophy reduces in Lemtrada patients
Study finds brain atrophy reduces in Lemtrada patients
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 1675 Views
-
Last post by NHE
-
- 0 Replies
- 13548 Views
-
Last post by accordingnature495
-
- 0 Replies
- 1973 Views
-
Last post by NHE
-
- 0 Replies
- 1292 Views
-
Last post by NHE
-
- 4 Replies
- 1635 Views
-
Last post by NHE
-
- 0 Replies
- 1683 Views
-
Last post by NHE
-
- 0 Replies
- 2118 Views
-
Last post by frodo
-
- 0 Replies
- 1012 Views
-
Last post by frodo
-
- 3 Replies
- 5050 Views
-
Last post by NHE